Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2015 Sep 8;5:13904. doi: 10.1038/srep13904

Dystrophin deficiency reduces atherosclerotic plaque development in ApoE-null mice

Annelie Shami 1,a, Anki Knutsson 1, Pontus Dunér 2, Uwe Rauch 1, Eva Bengtsson 2, Christoffer Tengryd 2, Vignesh Murugesan 1, Madeleine Durbeej 1, Isabel Gonçalves 2,3, Jan Nilsson 2, Anna Hultgårdh-Nilsson 1
PMCID: PMC4561962  PMID: 26345322

Abstract

Dystrophin of the dystrophin-glycoprotein complex connects the actin cytoskeleton to basement membranes and loss of dystrophin results in Duchenne muscular dystrophy. We have previously shown injury-induced neointima formation of the carotid artery in mice with the mdx mutation (causing dystrophin deficiency) to be increased. To investigate the role of dystrophin in intimal recruitment of smooth muscle cells (SMCs) that maintains plaque stability in atherosclerosis we applied a shear stress-modifying cast around the carotid artery of apolipoprotein E (ApoE)-null mice with and without the mdx mutation. The cast induces formation of atherosclerotic plaques of inflammatory and SMC-rich/fibrous phenotypes in regions of low and oscillatory shear stress, respectively. Unexpectedly, presence of the mdx mutation markedly reduced the development of the inflammatory low shear stress plaques. Further characterization of the low shear stress plaques in ApoE-null mdx mice demonstrated reduced infiltration of CD3+ T cells, less laminin and a higher SMC content. ApoE-null mdx mice were also found to have a reduced fraction of CD3+ T cells in the spleen and lower levels of cytokines and monocytes in the circulation. The present study is the first to demonstrate a role for dystrophin in atherosclerosis and unexpectedly shows that this primarily involves immune cells.

Atherosclerosis is the most important cause of acute cardiovascular events including myocardial infarction and stroke1. An important step in the development of atherosclerotic plaques is the binding of lipids to proteoglycans of the extracellular matrix (ECM)2, and the subsequent modification/oxidation and uptake of these lipids by intimal macrophages3. Lipid-filled macrophages accumulate within the lesion as foam cells4, which, together with the endothelial cells, produce cytokines and growth factors that activate vascular smooth muscle cells (SMCs) in the media of the artery wall5,6.

In the vessel wall endothelial cells reside on and SMCs are surrounded by a basement membrane, that, in addition to providing structural support, functions as a growth factor reservoir, directs tissue organization and presents binding sites for cell adhesion molecules and ligands for cell receptors, as well as affects cell signalling, differentiation, proliferation and migration7. The basement membrane consists mainly of the ECM components laminin, collagen type IV (a non-fibrillar collagen), perlecan and nidogen8.

Dystrophin, an intracellular protein located at the cytoplasmic face of the plasma membrane in both SMCs and skeletal muscle cells9,10,11,12, connects the actin cytoskeleton to perlecan and laminin α2-chains in the basement membrane13. The connection is made through association with the dystrophin-glycoprotein complex (DGC), comprised of transmembrane and cytosolic proteins. In addition to dystrophin, it includes α- and β-dystroglycans, α-, β-, γ- and δ-sarcoglycans, sarcospan and the syntrophins14,15,16,17. The DGC in skeletal muscle is thought to protect muscle fibres from damage caused by mechanical forces during muscle contraction13,18,19.

Loss of dystrophin expression leads to Duchenne muscular dystrophy (DMD; an X-linked recessive muscle disorder), which is the most common form of muscular dystrophy affecting one in 3500 male births20,21. Muscle wasting is progressive and the life span of afflicted patients is shortened to 20–30 years22. Similarly, the mdx (X-chromosome-linked muscular dystrophy) mouse23, that lacks full-length dystrophin due to a point mutation24,25, also develops muscular dystrophy, though in a much milder form compared to DMD patients26.

We have previously found evidence for a role of dystrophin in activation of the repair processes carried out by SMC in injured arteries27. These studies showed that SMCs down-regulate dystrophin as they de-differentiate from contractile to synthetic phenotype and that mdx mice are characterized by increased neointima formation in response to collar injury of the carotid artery. Based on this work along with several previous reports of an altered vasculature in the mdx mouse28,29,30 we hypothesize that dystrophin may play a role in atherosclerosis by controlling the recruitment of medial SMCs into the lesions, a process of critical importance for maintaining plaque stability. To test this possibility that dystrophin-deficiency would lead to the formation of larger and more SMC-rich plaques we generated mdx mice on an Apolipoprotein E (ApoE)-null background.

Materials and Methods

Materials and Methods may be found in more detail in the online data supplement.

Animals and In Vivo Alteration of Shear Stress

ApoE-null mice (a gift from Prof. Stefan Jovinge, Lund University, Sweden) were crossed with mdx mice (C57/10ScSn-mdx/J from Jackson Laboratory). For the current experiments ApoE-null mdx (ApoE/mdx) mice were used with ApoE-null mice as controls. Periadventitial cast placement to produce standardized changes in shear stress was performed as described previously by Cheng et al.31. Briefly, casts were placed around the right carotid artery of female 18-week-old mice. Mice were kept on a Western diet (R368: 0.15% cholesterol, 21% fat from Lantmännen, Sweden) starting two weeks before surgery until sacrifice at 30 weeks of age. All experiments involving mice were approved by the Malmö/Lund Ethical Committee for Animal Research (Sweden) and were carried out in accordance with the approved guidelines.

Histology, immunohistochemistry and immunofluorescence

Flat preparations of aortas were stained with Oil Red O.

For immunofluorescence, antibodies against laminin (α1/β1/γ1 chains, L9393, Sigma-Aldrich, Stockholm, Sweden) and Caspase-3 (ab4051, Abcam, Cambridge, UK) were used with a was Cy3-conjugated secondary antibody (goat anti rabbit Ig, Jackson ImmunoResearch Laboratories Inc. Baltimore Pike, PA, USA).

Sections of mouse carotid artery plaque were stained using primary antibodies against smooth muscle α-actin (α-SMA; clone 14A, Sigma-Aldrich), CD31 (clone SZ31, Dianova GmbH, Hamburg, Germany), mac2 (Cedarlane; Burlington, ON, Canada), CD3(ab16044-100, Abcam) and smooth muscle myosin heavy chain 11 (ab125884, Abcam). Sections were counterstained with Mayer’s hematoxylin (Histolab, Västra Frölunda, Sweden).

Analysis of plasma cytokines and cholesterol

The colorimetric assay Infinity Total Cholesterol (Thermo Scientific, Liverpool, U.K.) was used to quantify total plasma cholesterol and the Bio-Plex Pro Mouse Cytokine Assay (BIO-RAD, Hercules, CA, USA) was used to quantify plasma cytokine concentrations of interleukin (IL)-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-17A, interferon-γ (IFNγ) and tumour necrosis factor-α (TNF-α). Both analyses were performed according to instructions from the manufacturer.

Flow cytometry

Splenocytes and blood leukocytes from ApoE-null and ApoE/mdx- mice were stained with flourochrome-conjugated antibodies and were captured and analysed with a CyAn ADP flow cytometer (Beckman Coulter, High Wycombe, UK) using Summit software (Dako, Fort Collins, Colorado, USA). Erythrocytes were removed using red blood cell lysing buffer (Sigma, St. Louis, MO, USA). Fc receptors were blocked before extra- and intracellular staining (FcR; CD16/32). The following antibodies were used; CD3-PE/Cy7, CD4-PB, IL-5-PE, IFNγ-PE, IL-17-APC, Ly6c-PE/Cy7 and CD115-APC (Biolegend, San Diego, CA).

Statistical methods

Image analysis was performed using BioPix iQ software (BioPixAB, Gothenburg, Sweden). Positive immunoreactivity was quantified and expressed as percentage positively stained lesion area (relative to the total lesion size). Immunofluorescence was scored blindly on a scale from 1 to 5 according to the extent of positive staining in the lesion (with 5 representing the most extensive immunofluorescence). Lesion size of carotid artery plaques is expressed as intima/media ratio and area (μm2) and is the mean value of four sections 15 μm apart collected where each lesion was at its largest.

Samples were not normally distributed and Mann-Whitney U test (two-tailed) was performed using GraphPad Prism version 6.05 for Windows, GraphPad Software, San Diego, California, USA, www.graphpad.com). P-values < 0.05 were considered statistically significant. Values are presented as median with interquartile range (25th percentile to 75th percentile; IQR) with error bars representing IQR in graphs. Sample size is expressed as n.

Results

In order to investigate how the connection between cells and basement membranes influences atherogenesis, atherosclerotic lesions were induced in Apolipoprotein E (ApoE)-null mice and ApoE-null mice with the mdx mutation (referred to as ApoE and ApoE/mdx mice throughout this report) through a shear stress-modifying periadventitial cast placed around the right carotid artery31. The cast is thus placed around non-curved, non-branched region of the carotid artery where plaques do not naturally form—even in ApoE mice given a Western diet (as in the present study). Due to the tapered shape of the cast, a region of low shear stress induced plaques of a more inflammatory phenotype (i.e. containing a higher ratio of macrophages) proximal to the cast, and the region of oscillatory shear stress induced plaques of a more fibrous phenotype (i.e. containing a higher ratio of collagenous ECM) distal to the cast (Supplementary Fig. S1). The endothelium remained intact in both types of lesions, as shown by CD31 immunoreactivity (Supplementary Fig. S1). In the region of high shear stress inside the cast no plaques were formed. There was no difference in plasma levels of cholesterol or triglycerides in ApoE compared to ApoE/mdx mice (Supplementary Fig. S2).

Lack of dystrophin reduces plaque formation in the low-shear stress region and in the aorta

In the ApoE/mdx mouse, carotid artery plaques developing in the low shear stress region were smaller than the plaques formed in the same region in ApoE mice (P < 0.0001, Fig. 1a–f). Plaque sizes in the oscillatory shear stress region were similar in ApoE and ApoE/mdx mice. Development of atherosclerosis in the aorta, as assessed by en face Oil Red O staining, was reduced by almost 60% in ApoE/mdx mice as compared to ApoE mice (Fig. 1g and Supplementary Fig. S3).

Figure 1. Reduced atherosclerotic burden in ApoE/mdx mice.

Figure 1

Open in a new tab

Representative sections of Masson’s trichrome stain from low shear stress (a–b) and oscillatory shear stress (c–d) plaques in ApoE- and ApoE/mdx mice. Plaque size represented by plaque/media ratio (e) and total plaque size (f). Quantification of Oil Red O-stained flat preparations of aortas from ApoE and ApoE/mdx mice (g). Scale bars represent 100 μm and Mann-Whitney U test was used.

Dystrophin deficiency increases the SMC content of low shear but not of oscillatory shear stress plaques

Along with smaller size, increased cell density was found in low shear stress plaques from ApoE/mdx compared to low shear stress plaques from ApoE mice (P = 0.0231, Fig. 2a). Smooth muscle α-actin (α-SMA) immunoreactivity—primarily found in the fibrous cap—was increased in low shear stress-plaques from ApoE/mdx mice compared to plaques from the same region in ApoE mice (2.2 (0.8–4.2)% versus 8.3 (3.6–18.0)%, P = 0.0011; Fig. 2b–f). These plaques also contained increased amounts of smooth muscle myosin heavy chain (p = 0.0048, Supplementary Fig. S4), another SMC marker associated with a differentiated phenotype32. SMC content as assessed by both markers was similar in oscillatory shear stress-plaques of both genotypes. There was no difference in cell proliferation (Ki67), apoptosis (caspase-3) or in the ratios of macrophage (mac-2) or endothelial cell (CD31) immunoreactivity in either type of plaque (Supplementary Fig. S1, S5 and S6). Consequently, the increase in SMCs appears to account for the increased cell density found in low shear stress-plaques from ApoE/mdx mice.

Figure 2. Increases in cell density and smooth muscle cells.

Figure 2

Open in a new tab

Increased cell density (a) and smooth muscle cell content (b)—the latter as measured by the relative content of smooth muscle α-actin (α-SMA)—in low shear stress plaques from ApoE/mdx mice compared to ApoE mice. Representative α-SMA stained sections are shown in (c–f). Scale bars represents 100 μm and Mann-Whitney U test was used.

Lack of dystrophin affects laminin expression in the plaque/lumen interface

In the smaller low shear stress plaques of ApoE/mdx mice we also found the laminin expression to be altered. Utilizing an antibody against laminin chains α1, β1 and γ1, thereby detecting the vast majority of the laminin isoforms, we found that low, but not oscillatory, shear stress carotid plaques from ApoE/mdx mice contained less laminin compared to plaques from ApoE mice (p = 0.0004, Fig. 3). Laminin-positive immunoreactivity was typically found in the media and in the plaque region facing the vessel lumen.

Figure 3. Decreased immunoreactivity for laminin in low shear stress plaques in ApoE/mdx compared to ApoE mice.

Figure 3

Open in a new tab

Representative images showing laminin immunoreactivity in low shear stress plaques are found in (a,b), and oscillatory shear stress plaques in (c,d). Plaques from ApoE mice are found in (a,c), and plaques from ApoE/mdx mice in (b,d). Quantification are found in e. Nuclei are stained blue with DAPI and autofluorescence is shown in green. Scale bars represent 100 μm and Mann-Whitney U test was used.

Lack of dystrophin decreases accumulation of CD3+ T cells in low shear stress-plaques

To determine if the reduced development of atherosclerosis in ApoE/mdx mice involved changes in vascular inflammation we analysed the macrophage and T cell accumulation in plaques from the low and oscillatory shear stress region of the carotid artery. Plaques from ApoE/mdx demonstrated a marked reduction in CD3+ T cell numbers in both low shear stress (0 (0–3.8) versus 5.0 (1.0–12.7) cells/0.1 mm2, p = 0.02 and oscillatory shear stress lesions (1.9 (1.0–4.2) versus 3.8 (2.2–8.1) cells/0.1 mm2, p = 0.04) (Fig. 4 and Supplementary Fig. S7), while there was no difference in macrophage immunoreactivity (Supplementary Fig. S6).

Figure 4. Decrease in T cell plaque content.

Figure 4

Open in a new tab

The number of T cells relative to plaque size was decreased in low shear stress plaque from ApoE/mdx compared to ApoE mice (as determined through Mann-Whitney U test).

Dystrophin deficiency affects the immune cell composition in the spleen and circulation

To determine if the reduced accumulation of CD3+ T cells in atherosclerotic lesions of ApoE/mdx mice reflected a general effect of dystrophin deficiency on the immune system we analysed T cell and monocyte populations in the spleen and in the circulation. ApoE/mdx mice were found to have a lower fraction of CD3+ cells in spleen (Fig. 5a). The fraction of both CD3+ CD4+ and CD3+ CD4− T cells were reduced in ApoE/mdx as compared with in ApoE mice (9.7 (8.9–10.5)% versus 16.2 (11.9–18.4)%, p = 0.0006) and 21.0 (19.0–23.2)% versus 25.1 (22.5–29.5) %, p = 0.02; respectively). Further characterization of the CD4+ T cells revealed decreased IFNγ+ T cells, but increased IL5+ T cells in ApoE/mdx mice, whereas Tregs (CD25+ FoxP3+) or IL17+ CD3+ cells did not differ between ApoE/mdx mice or ApoE mice (Fig. 5b–e). In addition, ApoE/mdx mice displayed a lower fraction of monocytes in blood, as well as decreased inflammatory Ly6cHigh monocytes (Fig. 5f–g).

Figure 5. Lack of dystrophin in high fat diet fed apoE mice results in decreased T cells and monocytes.

Figure 5

Open in a new tab

Quantification of frequencies of CD3+ splenocytes (a), IFNγ+ (b), IL5+ (c), IL-17+ (d) and FoxP3+ CD25+ (e) among T cells, and CD115+ (f) and Ly6CHigh CD115+ (g) among PBMCs with comparisons made through the Mann-Whitney U test.

To investigate if the differences in immune cells were due to the Western diet, we analysed immune cells in chow fed mice. The fraction of CD3+ splenocytes was decreased also in chow fed ApoE/mdx mice (Supplementary Fig. S8). Furthermore, both CD3+ CD4+ (13.9% (12.4–15.8)% versus 19.2% (16.9–20.9)%, p = 0.001) and CD3+ CD4− (17.7% (16.5–17.9)% versus 19.8% (19.0–21.5)%, p = 0.007) fractions were decreased in ApoE/mdx. The fractions of monocytes or inflammatory Ly6Chigh monocytes in blood did not differ between chow fed ApoE/mdx and ApoE mice (Supplementary Fig. S8).

Lack of dystrophin results in an altered cytokine profile in plasma

As the development of both carotid and aortic plaques was affected in the ApoE/mdx mouse, we investigated whether any systemic effects on inflammatory response existed in this mouse. Indeed, the cytokines interleukin (IL)-2, −4, −6, −10, −12p70, −13, −17 and IFNγ were all down-regulated in plasma from ApoE/mdx mice compared to the ApoE mice (Table 1). The cytokine profile was similarly affected in mice that had been given regular chow with a down-regulation of IL-2, −4, −6, −13 and TNFα ApoE/mdx mice, demonstrating that this effect was not dependent on the Western diet (Supplementary Table S1).

Table 1. Cytokine levels in plasma from ApoE and ApoE/mdx mice on a high-fat diet (n = 28 for both genotypes).

Cytokines Plasma levels (pg/ml)
 P values
ApoE ApoE/mdx
IL-2 30.1 (22–50.5) 19.41 (10.1–27.8) 0.0005
IL-4 14.6 (11.3–17.6) 9.9 (7.8–11.9) <0.0001
IL-5 46.4 (30.7–55.5) 32.8 (14.2–43.3) NS
IL-6 25.2 (17.2–40.1) 20.0 (11.9–28.1) 0.0456
IL-10 155.6 (90.1–205.1) 91.1 (47.2–164.58) 0.0414
IL-12p70 550.2 (467.7–765.4) 409.5 (278.7–564.2) 0.0150
IL-13 1431 (733.6–1920) 930 (155.0–1269) 0.0101
IL-17 60.5 (38.3–78.9) 43.1 (29.3–59.3) NS
IFNγ 30.3 (14.2–39.7) 17.7 (5.2–30.3) 0.0303
TNFα 1384 (778.3–1936) 1532 (839.2–1532) NS
Open in a new tab

The Mann-Whitney U test was used and values are shown as median with interquartile range.

Discussion

Dystrophin is primarily recognized for its role in connecting muscle cells to the surrounding ECM. We have previously shown that vascular SMCs down-regulate dystrophin as they modulate from expressing a contractile to synthetic phenotype, a critical phenomenon in vascular repair responses as well as in the formation of atherosclerotic plaques. Lack of dystrophin was also found to be associated with enhanced neointima formation in response to carotid injury in mice. Against this background we postulated that ApoE/mdx mice would develop larger, more stable and SMC-rich atherosclerotic lesions. However, although the inflammatory low shear stress lesions indeed were found to contain more SMCs there was no difference in either size or SMC content in the more fibrous oscillatory shear stress lesions. Moreover, there was an unexpected reduction of plaque development both at the low shear stress site and in the aorta. This was accompanied by a marked reduction of T cell infiltration in the plaques as well as a more general suppression of immunity with reduced T cell levels in the spleen, lower plasma cytokines and less circulating monocytes including the inflammatory Ly6Chigh type. Taken together these observations (summarized in Suppl. Fig. S9) support the notion that dystrophin is involved in controlling the recruitment of SMC into inflammatory atherosclerotic lesions but unexpectedly also the dystrophin play an even more important role in atherosclerosis by controlling the immune responses that contributes to plaque development. Notably, whereas atherosclerotic plaques in ApoE/mdx mice contained markedly less T cells there was no difference in the macrophage content.

The effect of dystrophin deficiency on the immune system is not well characterized. The muscular dystrophy in Duchenne patients and mdx mice is associated with local inflammatory responses believed to contribute to myofiber death33,34. However, the inflammatory process in Duchenne differs from that of most other autoimmune and infectious myopathies in that fewer T cells accumulate in affected tissues35,36. The reason for the relative lack of T cell involvement in the inflammatory response to Duchenne muscular dystrophy remains to be fully elucidated, but Cascabulho and co-workers have shown that T cells from mdx mice are characterized by reduced endothelial homing due to shedding of CD62 ligand. These observations are well in line with the reduced accumulation of T cells found in atherosclerotic plaques of ApoE/mdx mice in our study. Additionally, we observed a relative decrease in the spleen T cell content as well as reduced levels of T cell-derived cytokines in plasma in ApoE/mdx mice suggesting that dystrophin deficiency may influence the development of the immune system. T cells are known to play an important role in the development of atherosclerosis and it is reasonable to assume that the reduced development of atherosclerosis in ApoE/mdx mice at least in part is explained by a lower T cell recruitment into lesion-prone arterial sites. Among CD4+ T cells, TH1 cells are considered pro-atherogenic while a TH2 response appears to have atheroprotective qualities37 characterization of CD4+ T cells isolated from the ApoE/mdx spleen revealed a T cell response that appeared to favour the more atheroprotectiveTH2 rather than aTH1 response; another possible factor in the development of smaller low shear stress plaques in ApoE/mdx mice. A molecular mechanism explaining the reduced fraction of CD3+ T cells in the spleen can refer to modifications of the basement membrane surrounding the dystrophin-defective SMCs and endothelial cells. The T cells enter the white pulp of the spleen through open arterioles, which contains one to two layers of SMCs and one hypothesis would be that the altered basement membrane, including less laminin, would make adhesion and migration of the T cells less effective. A similar phenomenon may also explain the reduced infiltration of CD3+ T cells in the inflammatory low shear stress lesions.

Observations of reduced circulating levels of IL-6 and pro-inflammatory Ly6Chigh monocytes in ApoE/mdx mice also suggested a general dampening of inflammatory activation as a result of dystrophin deficiency. These findings are in contrast to a previous study35 that found expression of several cytokines, including IL-2, −4 and TNFα, to be elevated in muscle and spleen of mdx compared to wild type mice. However, the possible discrepancy between these results may be explained by our use of ApoE mice that have higher levels of circulating low density lipoprotein (LDL)—in this study, also exacerbated by fatty diet—that likely serves as inflammatory stimuli, possibly affecting baseline cytokine profiles. It is thus interesting to note that the ApoE/mdx mouse, while under the influence of two possible inflammatory stressors—potentially inflamed skeletal muscle, as reported in the study by Vetrone et al.35, and circulating LDL—has lower plasma cytokine levels. Indeed, together with the decreased growth of low shear stress plaques in ApoE/mdx mice—plaques with an inflammatory phenotype—one can hypothesize a muted effect on the response of immune cells in these mice, involving a decreased response to inflammatory stimulus or altered release of inflammatory stimulus, such as cytokines, or a combination of the two.

The original hypothesis with our study was that ApoE/mdx mice would develop larger and more SMC-rich atherosclerotic plaques. With the exception of an increased content of SMC in the inflammatory low shear stress plaques this turned out not to be the case. We have previously shown that mdx mice are characterized by increased neointima formation in response to collar injury of the carotid artery. This neointima is formed by SMC recruited from the media and the process resembles in many ways the fibrous plaques that develop in the oscillatory shear stress region of the ApoE/mdx mice on high fat diet. The lack of effect of dystrophin deficiency on the formation of these plaques remains to be elucidated but may be due to the increased complexity of the atherosclerotic disease process as compared with the repair responses to mechanical injury. While the mechanically induced lesions in our first study27 consisted almost solely of SMCs and ECM, the atherosclerotic lesions in the present study develop due to modifications in fluid shear stress rather than mechanical stress. In addition, this model includes the atherosclerosis-prone ApoE-null mouse on a fatty diet. In this mouse, lipids as well as inflammatory cells and necrotic areas are found in lesions induced by shear stress—therefore the resulting lesions more closely resemble the human atherosclerotic plaque. Thus, the additional influence of lipids and inflammation on lesion development may explain why lesion size was affected differently by the mdx mutation in the two experimental models used. In favour of this hypothesis is also the finding that there was no difference in plaque size between genotypes in the oscillatory shear stress region. These plaques represent an intermediate plaque phenotype; while they do contain inflammatory cells, the relative macrophage content is significantly decreased and the collagen content significantly increased in comparison to low shear stress plaques38.

The increase in SMCs in the inflammatory low shear stress plaques may be explained by an increased migration by these cells. The SMC in the artery wall is highly dependent on an intact basement to remain in a differentiated phenotype. Once the composition of the basement membrane is being altered/degraded the SMC becomes activated with capacity to both migration and proliferation. It has been demonstrated that especially the laminin content is of importance39,40. The non-functional dystrophin in the mdx mouse results in altered composition in the basement membrane and a subsequent disrupted connection between the SMC, the basement membrane and the ECM18. It is likely that this environment favors a transition to a more de-differentiated phenotype with increased migration and proliferation. Indeed, increased migration has been found in human mesenchymal tumor cells with DMD deletions which inactivate the larger dystrophin isoform41.

Dystrophin is expressed in vascular SMCs as well as in endothelial cells12,28,42,43. Expression has been reported in large arteries as well as veins with contractile properties, and dystrophin is thus suggested to have an active part in the mechanical resistance of the muscle membrane44. While shear stress itself is not altered in mdx mice, Loufrani et al.28 found that the ability of endothelial cells to produce the vasorelaxant nitric oxide (NO) in response to shear stress was decreased. The same group later also observed inability of mdx arteries to adapt to chronic changes in blood flow with diameter and wall thickness increase or endothelial NO synthase expression and NO-dependent dilation29. Altered biomechanical properties in mdx carotid arteries were also reported by Dye et al.30, in that these arteries exhibited greater circumferential and axial stiffness. Dystrophin tends to be found in terminally differentiated cells20, and, with the exception of the cells lining the lumen and making up the fibrous cap, SMCs found in atherosclerotic plaques appear to exist in a more dedifferentiated state as activation and phenotypic modulation is required in order to leave the tunica media. As a result, dystrophin expression in SMCs in the deep plaque tissue is likely down-regulated in the same way as for example α-SMA and smooth muscle myosin heavy chain. We have previously analysed expression of dystrophin, along with β-dystroglycan and β-sarcoglycan, in primary aortic murine SMCs in vitro27, and found mRNA for all three proteins to be heavily reduced as the SMC phenotype switched from a contractile to a more synthetic state. This may indicate a lower degree of dependence on ECM interaction via the DGC as dedifferentiated SMCs change their expression of surface receptors45, such as integrins, to be able to bind to additional types of collagen and laminin chains.

In conclusion, with this study we present for the first time a role for dystrophin and the DGC in atherosclerotic plaque development. The results demonstrate that absence of dystrophin in an ApoE-null background results in attenuated atherosclerotic plaque development, accompanied by an increased proportion of differentiated SMCs and decreased proportion of T cells in plaques of an inflammatory phenotype. One potential underlying mechanism is altered involvement by the immune system and our study provides novel insight of a potential role for dystrophin in immunity.

Additional Information

How to cite this article: Shami, A. et al. Dystrophin deficiency reduces atherosclerotic plaque development in ApoE-null mice. Sci. Rep. 5, 13904; doi: 10.1038/srep13904 (2015).

Supplementary Material

Supplementary Information
srep13904-s1.pdf (858.7KB, pdf)

Acknowledgments

We thank Gunnel Roos, Lena Sundius, Mihaela Nitulescu, Ana Persson, Fong To and Ingrid Söderberg for expert technical assistance, and Kinga Gawlik for valuable discussion. Sources of funding: This research was funded by the Swedish Heart-Lung Foundation, the Swedish Research Council, Swedish Foundation for Strategic Research, Alfred Österlund Foundation, the Crafoord Foundation, Vinnova and Thelma Zoéga’s Foundation, Marianne and Marcus Wallenberg Foundation, Swedish Medical Society, Lundström’s foundations and Skåne university hospital grants.

Footnotes

Author Contributions A.S. helped design the study, participated in animal experiments, performed and analysed immunohistochemistry, interpreted results and drafted the manuscript text. A.K. participated in study design and animal experiments. P.D. performed and interpreted immunological experiments U.R. performed immunofluorescence stainings. E.B. interpreted immunological experiments and helped draft the manuscript. C.T. performed immunofluorescence stainings. V.M. performed histological stainings. M.D. and I.G. participated in study design. J.N. participated in study design and helped draft the manuscript. A.H.N. designed the study, interpreted data and helped draft the manuscript. All authors reviewed the manuscript.

References

  1. Laslett L. J. et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol 60, S1–49 (2012). [DOI] [PubMed] [Google Scholar]
  2. Skalen K. et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417, 750–754 (2002). [DOI] [PubMed] [Google Scholar]
  3. Galkina E. & Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 27, 2292–2301 (2007). [DOI] [PubMed] [Google Scholar]
  4. Chait A. & Wight T. N. Interaction of native and modified low-density lipoproteins with extracellular matrix. Current opinion in lipidology 11, 457–463 (2000). [DOI] [PubMed] [Google Scholar]
  5. Chamley-Campbell J. H. & Campbell G. R. What controls smooth muscle phenotype? Atherosclerosis 40, 347–357 (1981). [DOI] [PubMed] [Google Scholar]
  6. Gabbiani G., Kocher O., Bloom W. S., Vandekerckhove J. & Weber K. Actin expression in smooth muscle cells of rat aortic intimal thickening, human atheromatous plaque, and cultured rat aortic media. J Clin Invest 73, 148–152 (1984). [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. LeBleu V. S., Macdonald B. & Kalluri R. Structure and function of basement membranes. Experimental biology and medicine 232, 1121–1129 (2007). [DOI] [PubMed] [Google Scholar]
  8. Adiguzel E., Ahmad P. J., Franco C. & Bendeck M. P. Collagens in the progression and complications of atherosclerosis. Vasc Med 14, 73–89 (2009). [DOI] [PubMed] [Google Scholar]
  9. Zubrzycka-Gaarn E. E. et al. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature 333, 466–469 (1988). [DOI] [PubMed] [Google Scholar]
  10. Arahata K. et al. Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide. Nature 333, 861–863 (1988). [DOI] [PubMed] [Google Scholar]
  11. Bonilla E. et al. Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell 54, 447–452 (1988). [DOI] [PubMed] [Google Scholar]
  12. Hoffman E. P., Hudecki M. S., Rosenberg P. A., Pollina C. M. & Kunkel L. M. Cell and fiber-type distribution of dystrophin. Neuron 1, 411–420 (1988). [DOI] [PubMed] [Google Scholar]
  13. Ervasti J. M. & Campbell K. P. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 122, 809–823 (1993). [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ervasti J. M., Ohlendieck K., Kahl S. D., Gaver M. G. & Campbell K. P. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345, 315–319 (1990). [DOI] [PubMed] [Google Scholar]
  15. Campbell K. P. & Kahl S. D. Association of dystrophin and an integral membrane glycoprotein. Nature 338, 259–262 (1989). [DOI] [PubMed] [Google Scholar]
  16. Yoshida M. & Ozawa E. Glycoprotein complex anchoring dystrophin to sarcolemma. Journal of biochemistry 108, 748–752 (1990). [DOI] [PubMed] [Google Scholar]
  17. Straub V. et al. epsilon-sarcoglycan replaces alpha-sarcoglycan in smooth muscle to form a unique dystrophin-glycoprotein complex. J Biol Chem 274, 27989–27996 (1999). [DOI] [PubMed] [Google Scholar]
  18. Ibraghimov-Beskrovnaya O. et al. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355, 696–702 (1992). [DOI] [PubMed] [Google Scholar]
  19. Petrof B. J., Shrager J. B., Stedman H. H., Kelly A. M. & Sweeney H. L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 90, 3710–3714 (1993). [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hoffman E. P., Brown R. H. Jr. & Kunkel L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919–928 (1987). [DOI] [PubMed] [Google Scholar]
  21. Emery A. E. Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscular disorders: NMD 1, 19–29 (1991). [DOI] [PubMed] [Google Scholar]
  22. Emery A. E. The muscular dystrophies. Lancet 359, 687–695 (2002). [DOI] [PubMed] [Google Scholar]
  23. Bulfield G., Siller W. G., Wight P. A. & Moore K. J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 81, 1189–1192 (1984). [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ryder-Cook A. S. et al. Localization of the mdx mutation within the mouse dystrophin gene. EMBO J 7, 3017–3021 (1988). [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sicinski P. et al. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244, 1578–1580 (1989). [DOI] [PubMed] [Google Scholar]
  26. Dangain J. & Vrbova G. Muscle development in mdx mutant mice. Muscle & nerve 7, 700–704 (1984). [DOI] [PubMed] [Google Scholar]
  27. Rauch U. et al. Increased neointimal thickening in dystrophin-deficient mdx mice. PLoS One 7, e29904 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Loufrani L. et al. Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin. Circulation 103, 864–870 (2001). [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Loufrani L., Levy B. I. & Henrion D. Defect in microvascular adaptation to chronic changes in blood flow in mice lacking the gene encoding for dystrophin. Circ Res 91, 1183–1189 (2002). [DOI] [PubMed] [Google Scholar]
  30. Dye W. W., Gleason R. L., Wilson E. & Humphrey J. D. Altered biomechanical properties of carotid arteries in two mouse models of muscular dystrophy. Journal of applied physiology 103, 664–672 (2007). [DOI] [PubMed] [Google Scholar]
  31. Cheng C. et al. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 113, 2744–2753 (2006). [DOI] [PubMed] [Google Scholar]
  32. Gomez D. & Owens G. K. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res 95, 156–164 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Claflin D. R. & Brooks S. V. Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy. American journal of physiology. Cell physiology 294, C651–658 (2008). [DOI] [PubMed] [Google Scholar]
  34. Deconinck N. & Dan B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatric neurology 36, 1–7 (2007). [DOI] [PubMed] [Google Scholar]
  35. Vetrone S. A. et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 119, 1583–1594 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Dalakas M. C. Review: An update on inflammatory and autoimmune myopathies. Neuropathology and applied neurobiology 37, 226–242 (2011). [DOI] [PubMed] [Google Scholar]
  37. Schulte S., Sukhova G. K. & Libby P. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am J Pathol 172, 1500–1508 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Shami A. et al. Fibromodulin deficiency reduces low-density lipoprotein accumulation in atherosclerotic plaques in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 33, 354–361 (2013). [DOI] [PubMed] [Google Scholar]
  39. Hedin U., Bottger B. A., Forsberg E., Johansson S. & Thyberg J. Diverse effects of fibronectin and laminin on phenotypic properties of cultured arterial smooth muscle cells. J Cell Biol 107, 307–319 (1988). [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Thyberg J., Blomgren K., Roy J., Tran P. K. & Hedin U. Phenotypic modulation of smooth muscle cells after arterial injury is associated with changes in the distribution of laminin and fibronectin. J Histochem Cytochem 45, 837–846 (1997). [DOI] [PubMed] [Google Scholar]
  41. Wang Y. et al. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nature genetics 46, 601–606 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Miyatake M. et al. Possible systemic smooth muscle layer dysfunction due to a deficiency of dystrophin in Duchenne muscular dystrophy. Journal of the neurological sciences 93, 11–17 (1989). [DOI] [PubMed] [Google Scholar]
  43. Ito K. et al. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice. Human molecular genetics 15, 2266–2275 (2006). [DOI] [PubMed] [Google Scholar]
  44. Rivier F., Robert A., Hugon G. & Mornet D. Different utrophin and dystrophin properties related to their vascular smooth muscle distributions. FEBS letters 408, 94–98 (1997). [DOI] [PubMed] [Google Scholar]
  45. Moiseeva E. P. Adhesion receptors of vascular smooth muscle cells and their functions. Cardiovasc Res 52, 372–386 (2001). [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep13904-s1.pdf (858.7KB, pdf)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES